Immunology Case Study

Last updated: May 6, 2025

Immunology studies present specific challenges: their eCOA build can be complex, site staff must play a key role, and study duration can be very long whilst patients are in pain.

To overcome these challenges, Kayentis offers strong and global experience in immuno-inflammation trials, especially with:

experienced teams and a powerful solution to face eCOA complexities,
adapted options to support site staff,
and additional features for the comfort of the patient

Therefore, Kayentis contributes to the success and quality of immunology clinical trials.

Learn more in the case study 👇

Subscribe to our newsletter

Expanding investor confidence: The strategic value of Patient Reported Outcomes...

Leveraging the potential of Patient Reported Outcome (PRO) data to...

Gastrointestinal Tract Diseases Research: Moving Towards Patient-Centered Clinical Trials

Turning experience into evidence: PROs in IBD clinical research

BYOD on the rise

Strategies to promote BYOD adoption by clinical study sites

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

The critical importance of Patient Reported Outcomes (PROs) for Emerging Biopharma Companies – Webinar

July 9 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET

In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly....